Emerging drugs for celiac disease.

Area of Science:

• Gastroenterology
• Immunology
• Genetics

Background:

• Celiac disease is an immune-mediated disorder triggered by gluten in genetically susceptible individuals.
• It affects the small intestine and presents with diverse clinical and histopathological features.
• The current standard treatment, a strict gluten-free diet, is effective but challenging to adhere to and expensive.

Purpose of the Study:

• To review alternative and supplementary treatments for celiac disease.
• To evaluate the efficacy of novel therapeutic approaches beyond the gluten-free diet.

Main Methods:

• Systematic review of published English language literature.
• Examination of studies on alternative treatments for celiac disease.

Main Results:

• Oral recombinant glutenase (ALV003) demonstrated modest benefits in celiac disease patients adhering to a gluten-free diet.
• Other investigated immune-modulating therapies have yielded less positive results.
• Significant but limited benefits were observed in recent placebo-controlled trials.

Conclusions:

• Further long-term investigations in diverse patient populations are required.
• Alternative therapies may supplement the gluten-free diet but are not yet replacements.
• Research into other immune pathways in celiac disease pathogenesis is ongoing.